hydroxychloroquine has been researched along with Elevated Cholesterol in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "(1) Hydroxychloroquine has a possible anti-thrombotic action." | 2.38 | The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. ( Linker-Israeli, M; Metzger, AL; Stecher, VJ; Wallace, DJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Houssen, ME | 1 |
| El-Mahdy, RH | 1 |
| Shahin, DA | 1 |
| Inhoff, O | 1 |
| Peitsch, WK | 1 |
| Paredes, BE | 1 |
| Goerdt, S | 1 |
| Goebeler, M | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Wallace, DJ | 1 |
| Linker-Israeli, M | 1 |
| Metzger, AL | 1 |
| Stecher, VJ | 1 |
| Rahman, P | 1 |
| Gladman, DD | 1 |
| Urowitz, MB | 1 |
| Yuen, K | 1 |
| Hallett, D | 1 |
| Bruce, IN | 1 |
1 review available for hydroxychloroquine and Elevated Cholesterol
| Article | Year |
|---|---|
The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Topics: Animals; Antimalarials; CD8 Antigens; Humans; Hydroxychloroquine; Hypercholesterolemia; Interleukin- | 1993 |
5 other studies available for hydroxychloroquine and Elevated Cholesterol
| Article | Year |
|---|---|
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |
Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Biomarkers; Case-Control Studies; Creatinine; | 2016 |
Simvastatin-induced amyopathic dermatomyositis.
Topics: Aged; Biopsy; Dermatomyositis; Female; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reducta | 2009 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Cholesterol; Dose-Response Relationship, Drug; Dru | 1999 |